Navigation Links
Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences

GOTHENBURG, Sweden, February 1 /PRNewswire/ -- Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.

Annelie Skafte Persson, Cellectricon's Chief Executive Officer, said, "Cellectricon invents and develops advanced cell-based microfluidic screening solutions for applications in drug discovery and basic research. Cellectricon has an extensive intellectual property portfolio with novel cell-based screening technologies based on fifteen years of world-renowned research. To ensure a fair return on our research and development efforts we must protect our intellectual property and we will take all necessary steps to prevent its unauthorized use."

Cellectricon's Chairman Lars-Eric Utterman added, "Cellectricon is a highly innovative company which has successfully launched several advanced screening systems on the life science market. Today's litigation is a strategic step to defend Cellectricon's intellectual property from being infringed."

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. Cellectricon has developed two pioneering high throughput screening platforms in close collaboration with leaders in the pharmaceutical industry. Used in preclinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput transfection for genomic screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

    Contact Details:

    Annelie Skafte Persson, CEO

    Susanne Fagerlund, VP Marketing & Communications

SOURCE Cellectricon AB

SOURCE Cellectricon AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
2. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
3. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
4. Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
5. Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
9. Arrow International Files and Mails Definitive Proxy Materials
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Post Your Comments:
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):